• Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compounds
• The company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressure
• Long-term studies have shown that high blood pressure can increase the risk of developing dementia in later life
• Experts, however, believe that hypertension medication could slow the pace of the cognitive decline
• In addition to helping hypertension patients keep their condition under control, Lexaria’s DehydraTECH-CBD, which has so far been shown to be safe and well tolerated, could potentially help reduce the risk of dementia

Blood pressure or BP typically refers to the pressure exerted by circulating blood against the walls of blood vessels, particularly large arteries and veins. This pressure fluctuates throughout the day depending on the activity in which one engages. However, in some instances, it can consistently cross the normal threshold, a condition known as high blood pressure or hypertension. Usually, and based on a 2017 guideline, a person is said to have high BP when the top reading on the blood pressure monitor, which represents the systolic blood pressure, is greater than 130 mmHg while the bottom reading, which denotes the diastolic pressure, is above 80 mmHg (https://cnw.fm/NVuKL).

The constant exertion of elevated pressure on blood vessels damages them by making them less elastic. According to the Centers for Disease Control (“CDC”), this decreases the flow of blood and oxygen to the heart and other body organs. And it is this depressed blood flow that causes progressive damage to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.